AUTEK(SZ:300595)2024-08-26 14:38Group 1: Financial Performance - The company spent 506 million CNY on acquiring 13 subsidiaries, with 25% paid in cash for tax purposes, and the remaining shares are under lock-up agreements [3] - The sales revenue for orthokeratology lenses in the first half of the year was 1.61 billion CNY, while the sales of other optical products and technical services amounted to 1.61 billion CNY [4] - The gross margin for care products increased significantly due to a higher proportion of self-produced care products sold [5] Group 2: Market Strategy - The company aims to position the scleral lens as a high-end optical product that can replace traditional contact lenses, thereby establishing a brand moat [3] - The pricing strategy for the scleral lens is still under development, with considerations for user affordability [3] - The company is transitioning its marketing approach from B2B to B2C, although specific ratios have not yet been calculated [5] Group 3: Investor Relations - The company emphasizes that improving performance and maintaining sustainable development are fundamental to enhancing its value [6] - There are ongoing efforts to boost investor confidence, including the implementation of a comprehensive optical development strategy [6] - The company has not disclosed any specific measures to address the decline in stock price but is committed to transparency in future communications [6]